Greek English

Contracted laboratory for Biomarkers

BIOANALYTICA GENOTYPE SA was established in December 2004 as a biotech startup aiming to provide specialised molecular cytogenetic research and application services to the biomedical Community.

 

Was funded by BIOANALYTICA SA, a leading stakeholder in the greek market for molecular diagnostics and laboratory infrastructure, and by the researcher Dr. Georgia Bardi, Associate Professor of Experimental Clinical Genetics at the Medical school of Lund University, Sweden and former Director of the Cytogenetics facility at Saint Savas Oncology hospital of Athens.

 

Is co-financed by the Greek General Secretariat of Research and Technology under the 3rd Community Support Program (03 Praxe 26).

 

 

Quality Management

Διαχείριση Ποιότητας

The quality management Plan (CRC) of BioAnalytikis-GenoTypos SA assures that the laboratory meets the defined standards of quality practice that complies with all regulatory and applied laws on patient safety and the quality of the lab, and that all the necessary actions to improve quality control.

 

Advantages:

 

  • Total quality management
  • State technology infrastructure
  • CE-IVD certified reagents
  • Wide range of experimental protocols and applications
  • Superb handling of the sample and transfer to a specific carrier, certified for organic/clinical materials.
  • Rapid analysis and communicate the outcome to enable the timely utilization of

BioAnalytica-Genotype SA serves the healthcare market by offering Cytogenetics and Molecular Genetics tests, designed to answer questions related to diagnosis, prognosis and therapy selection for hematologic and solid tumor cancers.